Compare BGB & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGB | ANGO |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.4M | 439.8M |
| IPO Year | N/A | 2004 |
| Metric | BGB | ANGO |
|---|---|---|
| Price | $11.11 | $10.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 185.2K | ★ 373.5K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $10.47 | $8.36 |
| 52 Week High | $12.65 | $13.99 |
| Indicator | BGB | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 42.72 |
| Support Level | $10.98 | $9.73 |
| Resistance Level | $11.89 | $11.06 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 39.39 | 1.20 |
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.